# Absci

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/absci

- Industry: Biotechnology
- Headquarters: Vancouver, US
- Website: www.absci.com/
- Total disclosed funding: $98M
- Latest round: Series E (Feb 22, 2021)
- Investors on record: 13

## About

Based in Washington, US, Absci Corp, formerly known as Absci LLC, was founded in 2011 by founder Jeremy Abelson. The company provides a deep learning-based biologics platform for drug creation and cell line development. In March 2021, AbSci, LLC raised USD 125 million in venture funding co-led by Casdin Capital and Redmile Group, with participation from ArrowMark Partners. In July 2021, Absci raised USD 200 million by offering 12.5 million shares on the Nasdaq under the ticker symbol ABSI, and as of this date, the company has 169 employees. In January 2025, Absci Corp. raised USD 20 million PIPE funding from AMD. The company works with biopharmaceutical companies by offering an integrated biology platform, a protein printing platform technology for protein engineering. Absci Corp screens novel drug variants based on the desired scaffold format and cell line used for manufacturing and streamlines the drug formulation process. The company also offers SoluPro, a platform for complex disulfide-bonded proteins in a soluble form, and SoluPure, a purification technology that eliminates downstream chromatography steps in the drug formulation process. The company will use the funding to strengthen artificial intelligence-driven drug discovery capabilities and expand the deployment of AMD hardware and software solutions in critical workloads.

## Funding rounds

- Series E, Feb 22, 2021, $5M — Merck Global Health Innovation Fund
- Series E, Oct 19, 2020, $65M — ArrowMark Partners, Phoenix Venture Partners, Redmile Group, Casdin Capital
- Series D, Dec 5, 2019, $10M — Oregon Venture Fund, Phoenix Venture Partners, WRF Capital, KBI Biopharma, Columbia Ventures Corporation, JSR Life Sciences, LLC
- Series C, May 30, 2018, $12M — AGC, Oregon Venture Fund, Phoenix Venture Partners, WRF Capital, Southern Company, Greenbridge Partners, Columbia Ventures Corporation
- Series B, Aug 14, 2017 — Phoenix Venture Partners
- Series A, Apr 11, 2016, $5.1M — Phoenix Venture Partners

## Investors

- Phoenix Venture Partners — Series A, Series B, Series C, Series D, Series E
- AGC — Series C
- Oregon Venture Fund (https://capitalatlas.ai/funds/oregon-venture-fund) — Series C, Series D
- WRF Capital (https://capitalatlas.ai/funds/wrf-capital) — Series C, Series D
- Southern Company — Series C
- Greenbridge Partners (https://capitalatlas.ai/funds/greenbridge-partners) — Series C
- Columbia Ventures Corporation — Series C, Series D
- KBI Biopharma — Series D
- JSR Life Sciences, LLC — Series D
- ArrowMark Partners — Series E
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series E
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series E
- Merck Global Health Innovation Fund (https://capitalatlas.ai/funds/merck-global-health-innovation-fund) — Series E